Investigation of the Frequency of CRP Gene Polymorphism in Rheumatoid Arthritis and Associations with CRP Level and Clinical Involvements of the Disease

SNP ID	Localization	Context sequence	Phenotype	Polymorphism
rs1205	Chromosome 1:159712443	(C/T)	MIM:123260	C/T Transition Substitution
rs1800947	Chromosome 1:159713648	(C/G)	MIM:123260	C/G Transversion Substitution
rs1130864	Chromosome 1:159713301	(A/G)	MIM:123260	A/G Transition Substitution

Table 2.

Socio-demographic and clinical characteristics of the patient-group

Age (years), mean ± SD	56,4 ± 9.7
Female sex, n (%)	100 (83.3)
The age of first symptom (years), mean ± SD	43,4 ± 9.7
The age of diagnosis (years), mean ± SD	47,2 ± 10.2
Smoking, n (%)	45 (37.5)
Family history, n (%)	21 (17.5)
Drug treatment, n (%)
Biologic	13 (10.8)
DMARD	107 (89.2)
DAS-28 >5.1, n (%)	36 (30)
Presence of lung involvement, n (%)	15 (12.5)
The first CRP>0.8, n (%)	109 (91,2)
The last CRP>0.8, n (%)	32 (26,3)
Autoantibodies
RF, n (%)	93 (77,5)
Anti-CCP, n (%)	78 (72,9)
ANA, n (%)	24 (22,0)

[i] DMARD: Disease-modifying anti-rheumatic drugs, DAS-28: Disease activity score-28, CRP: C-reactive protein, RF: rheumatoid factor, anti CCP: Anti-cyclic Citrullinated Peptide, ANA: Antinuclear antibody

Table 3.

Distributions of CRP gene polymorphisms and alleles of CRP gene polymorphisms in study groups

		Patient group	Control group n (%)	P value^a
rs1205 polymorphism	TT homozygous	15 (12.5)	17 (17.0)	0.429
rs1205 polymorphism	CT heterozygous	55 (45.8)	38 (38.0)	0.429
CC homozygous	50 (41.7)	45 (45.0)
rs1130864 polymorphism	TT homozygous	6 (5)	14 (14)	0.002
rs1130864 polymorphism	CT heterozygous	42 (35)	48 (48)	0.002
CC homozygous	72 (60)	38 (38)
rs1800947 polymorphism	CC homozygous	11 (9.2)	7 (7)	0.559
CG heterozygous	109 (90.8)	93 (93)
rs1205 allele	T	85 (35.4)	72 (36)	0.899
C	155 (64.6)	128(64)
rs1130864 allele	T	54 (22.5)	76 (38)	<0.001
C	186 (77.5)	124 (62)
rs1800947 allele	G	109 (45.4)	93 (46.5)	0.82
C	131 (54.6)	107 (53.5)

a Chi-square test.

Table 4.

Associations between the rates of rs1130864 polymorphism and sociodemographic characteristics, clinical features and laboratory results


	TT homozygous	CT heterozygous	CC homozygous	P value
The age of first symptom (years), median (IQR)	50(48–52)	43.5(37–50)	42(38–49.5)	0.154^a
The age of diagnosis (years), median (IQR)	56(52–58)	47(38–54)	47(42–52.5)	0.061^a
Delay time of diagnosis (years), median (IQR)	5.5(3–8)	2(1–5)	3(1–6)	0.279^a
Smoking, n (%)				0.448^b
+	3(6.7)	18(40)	24(53.3)	0.448^b
−	3(4)	24(32)	48(64)
Family history, n (%)				0.714^b
+	1(4.8)	9(42.9)	11(52.4)	0.714^b
−	5(5.1)	33(33.3)	61(61.6)
Drug treatment, n (%)				0.775^b
Biologic	1(7.7)	4(30.8)	8(61.5)	0.775^b
DMARD	5(4.7)	38(35.5)	64(59.8)
DAS-28 >5.1, n (%)				0.793^b
+	2(5.6)	11(30.6)	23(63.9)	0.793^b
−	4(4.8)	31(36.9)	49(58.3)
The first CRP>0.8, n (%)				0.625^b
+	5(4.6)	38(34.9)	66(60.6)	0.625^b
−	1(9.1)	4(36.4)	6(54.5)
The last CRP>0.8, n (%)				0.659^b
+	1(3.6)	12(42.9)	15(53.6)	0.659^b
−	5(5.4)	30(32.6)	57(62)
RF, n (%)				0.807^b
+	5(5.4)	34(36.6)	54(58.1)	0.807^b
−	1(3.7)	8(29.6)	18(66.7)
Anti-CCP, n (%)				0.804^b
+	3(3.8)	29(37.2)	46(59)	0.804^b
−	2(6.9)	11(37.9)	16(55.2)
Presence of lung involvement, n (%)				0.017^c
+	3(20)	4(26.7)	8(53.3)	0.017^c
−	3(2.9)	38(36.2)	64(61)
DAS 28 score, mean ± SD	4.8±0.65	4.7±0.55	4.9±0.5	0.140^d
The first ESR (mm/h), median (IQR)	40.5(21–59)	34.5(24–51)	39.5(28.5–53)	0.314^a
The final ESR (mm/h), median (IQR)	11.5(3–15)	11(5–17)	11.5(6–17.5)	0.943^a
The first CRP, (mg/dl), median (IQR)	7.5(4.3–30.7)	2.6(1.7–5.1)	2.8(1.4–4.9)	0.162^a
The final CRP(mg/dl), median (IQR)	0.2(0.1–0.5)	0.5(0.3–0.9)	0.5(0.2–0.7)	0.339^a
RF (IU/ml), median (IQR)	69(22–159)	137(30–324)	61(10–215)	0.214^a
Anti CCP (IU/ml) median (IQR)	122(11–74)	84(15–815)	20(18–1000)	0.664^a

a Kruskal-Wallis,

b Chi-Square Test,

c Fisher's test,

d One-way ANOVA, IQR: Interquartile Range (25–75 percentile)

DMARD: Disease-modifying anti-rheumatic drugs, DAS-28: Disease activity score-28, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, RF: rheumatoid factor, anti CCP: Anti-cyclic Citrullinated Peptide.

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/bjmg-2025-0003 | Journal eISSN: 2199-5761 (formerly 1311-0160) | Journal ISSN: 1311-0160

Journal RSS Feed

Language: English

Published on: Oct 8, 2025

Published by: Macedonian Academy of Sciences and Arts

In partnership with: Paradigm Publishing Services

Keywords:

C-reactive protein,

Genetic polymorphism,

İnflammation,

İnterstitial lung disease,

Rheumatoid arthritis

Related subjects:

Medicine,

Basic medical science,

Basic medical science, other

© 2025 S Biter, I Turk, G Varkal, S Dinkçi, E Erken, published by Macedonian Academy of Sciences and Arts
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 28 (2025): Issue 1 (June 2025)